Oslo, 20 January 2017 - Navamedic ASA today announced that the European Patent Office has granted a patent for Sippcoat® to be used in any urine handling system to help prevent bacteria migration. This brings with it significant longterm commercial potential for Navamedic.
"We are pleased to have been granted a European patent for Sippcoat, an
innovative encapsulated silicone-oil technology for biofilm inhibition in urine
drainage devices. The patent is another exciting development for Navamedic and
represents an important milestone in the commercialisation of the Sippi product
family. The patent means Sippcoat is protected to be used in any urine
collection bags, which yields major licensing opportunities and hence an
additional multi-million NOK market potential for Navamedic," says Magnus
Emmoth, CEO of Navamedic Medtech.
Sippcoat® is a soluble capsule, which incorporates silicone oil in an oil-
releasing mechanism. The mechanism is automatically activated by the patient
after application, and inhibits biofilm formation inside urine handling systems.
Biofilm formation is the root cause for bacterial growth on medical devices, and
the silicone oil helps prevent nosocomial infections in urine bags.
"Completed and initiated clinical studies will together enhance a strong body of
evidence supporting the bacteria-preventing properties of the innovative
Sippcoat-technology," says Magnus Emmoth.